Medical marijuana: Do the benefits outweigh the risks?

By |2018-01-25T14:27:56-08:00January 25th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

By Sheila Gupta, Tiffany Phalen, and Sanjay Gupta There is a need for additional treatment options to improve symptoms, enhance the quality of life (QOL), and reduce suffering among patients who have chronic medical illness. Medical marijuana (MM) has the potential to help patients who have certain medical conditions in states where it [...]

Tailored Exercise Can Be a Boon to People With Parkinson’s Disease

By |2021-11-11T17:14:58-08:00January 24th, 2017|Brief Bulletins from the Field, We Know Psychiatry|

In a surprise to the conservative treatments by neurologists, tailored exercise treatment programs are being developed by physical therapists to specifically counter the unique movement impairments associated with Parkinson’s by training patients to make big strong movements that incorporate the principles of tai chi and boxing. Treatments can, as well, [...]

Serum Insulin-Like Growth Factor-1 in Patients with De Novo, Drug Naïve Parkinson’s Disease: A Meta-Analysis

By |2015-12-14T16:33:03-08:00December 14th, 2015|We Know Psychiatry|

The results of this meta-analysis demonstrate that serum IGF-1 levels were significantly higher in de novo, drug-naïve PD patients compared with healthy controls. Nevertheless, additional endeavors are required to further explore the association between serum IGF-1 levels and diagnosis, prognosis and early therapy for PD.

Title

Go to Top